Article | August 5, 2019

Regulatory Agencies Encourage Use Of Adaptive Designs

Source: ICON Plc
Guidance-Puzzle-Regulatory-iStock-489087670

Over the past several years, regulators, including the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Japan’s Pharmaceuticals and Medical Device Agency (PMDA), have provided guidance on the use of adaptive design for clinical development, which has accelerated industry adoption of adaptive design trials.

The FDA’s Critical Path Initiative identifies adaptive design as key to improving trial efficiency. Early stopping, sample size optimization and changing allocation are based on interim estimates of dose and dose-response curve. The FDA encourages this approach because, “when properly implemented, [adaptive design] can reduce resource requirements, decrease time to study completion, and/or increase the chance of study success”.

The EMA welcomes studies utilizing adaptive design, recognizing that “such a design can speed up the process of drug development or can be used to allocate resources more efficiently without lowering regulatory standards.”

Read more about how FDA and EMA thinking on adaptive designs has progressed significantly, and support for the approach has strengthened, in the following brief history.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: